POLA1
ENSG00000101868
Target class
Enzyme
Chromosome
X
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- p180
- Target name
- POLA1
- Gene name
- DNA polymerase alpha 1, catalytic subunit
- Gene symbol
- POLA1
- Protein name
- DNA polymerase alpha catalytic subunit (EC 2.7.7.7) (DNA polymerase alpha catalytic subunit p180)
- POLA
- NSX
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 21.07
- Tissue specificity (Gini)
- 0.315
- Tissue specificity (tau)
- 0.764
- KEGG gene identifiers
- hsa:5422
- Protein interaction confidence
- 0.877617
- Protein interaction partners
- 81
- R-HSA-113501
- R-HSA-174411
- R-HSA-174430
- R-HSA-68952
- R-HSA-68962
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- R-HSA-69205
- R-HSA-9710421
- End position
- 24996986
- Start position
- 24693864
- Chromosome
- X
- Strand
- Forward
- Nucleus . Cytoplasm, cytosol . Note=In the cytosol, colocalizes with RNA:DNA hybrids with a speckled pattern. .
- Cytosol
- Nucleoplasm
Publication evidence
- PubMed 27019227
- Tissue specificity (tau)
- 0.7636
- Expression inequality (Gini)
- 0.314778
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 21.07
- Nerve - Tibial
- 11.78
- Ovary
- 9.43
- Cervix - Endocervix
- 9.16
- Uterus
- 8.92
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes21.07
- Nerve - Tibial11.78
- Ovary9.43
- Cervix - Endocervix9.16
- Uterus8.92
- Cervix - Ectocervix8.83
- Artery - Tibial8.64
- Fallopian Tube8.36
- Cells - Cultured fibroblasts7.59
- Vagina7.53
- Colon - Sigmoid7.21
- Bladder7.11
- Esophagus - Muscularis6.76
- Skin - Sun Exposed (Lower leg)6.66
- Skin - Not Sun Exposed (Suprapubic)6.55
- Breast - Mammary Tissue6.44
- Esophagus - Gastroesophageal Junction6.33
- Adipose - Subcutaneous6.29
- Brain - Cerebellar Hemisphere6.21
- Artery - Coronary6.14
- Artery - Aorta6.08
- Lung5.78
- Esophagus - Mucosa5.61
- Brain - Cerebellum5.47
- Prostate5.42
And 29 more, listed on the interactive page.
- GO:0000731
- GO:0006260
- GO:0006269
- GO:0006270
- GO:0006271
- GO:0006272
- GO:0006273
- GO:0006281
- GO:0006289
- GO:0006303
- GO:0032479
- GO:1904161
- GO:0000785
- GO:0005634
- GO:0005635
- GO:0005654
- GO:0005658
- GO:0005730
- GO:0005829
- GO:0016363
- GO:0000166
- GO:0003677
- GO:0003682
- GO:0003887
- GO:0005515
- GO:0008270
- GO:0019901
- GO:0034061
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor